PHT Corporation Co-Develops and Implements the Electronic Version of the Mini-International Neuropsychiatric Interview Questionnaire (M.I.N.I) for Global Clinical Trials

PHT Corporation Co-Develops and Implements the Electronic Version of the Mini-International Neuropsychiatric Interview Questionnaire (M.I.N.I) for Global Clinical Trials

PHT earns Preferred Provider status for licensing the electronic version of the M.I.N.I for use in clinical trials and research studies on the PHT SitePad® tablet system and the NetPRO™ web system

May 27, 2014 09:00 AM Eastern Daylight Time

PRO & eCOA Congress 2014

BOSTON & GENEVA--()--PHT Corporation announced the co-development and implementation of the Mini-International Neuropsychiatric Interview (M.I.N.I.) for electronic data collection within clinical trials researching the central nervous system (CNS). The electronic version of the M.I.N.I. instrument is available on the PHT SitePad® System, a large touch screen tablet for clinician use, and via the PHT NetPRO™ System which allows patients to provide data responses via web browsers for home-based screening. PHT is the leading provider of technologies used to collect patient-driven eData for clinical research.

The electronic version of the M.I.N.I. will enable mental health researchers to standardize their screening and diagnosis of psychiatric disorders. The electronic format with branching logic efficiently presents patients with a subset of the 381 questions that apply to them, reducing respondent burden and increasing ease of use. The tablet version is administered by trained clinicians at office visits. The web browser version is for patient home-based screening.

According to Christopher R. Gray, President of Medical Outcomes Systems, Inc., who developed the electronic version of the M.I.N.I., "It's a great pleasure to align with a provider who is equally concerned with content integrity, and continuously innovating for global trials. Using the electronic version of the M.I.N.I. on the SitePad System will enable clinical researchers to diagnose patients more efficiently and help improve clinical care and research." There are more than 14,753 new and ongoing clinical trials and research studies for psychiatric disorders currently listed on the clinicaltrials.gov website.

PHT President and CEO Philip Lee said, "PHT continues to lead clinical trial innovation by being the first and only preferred eCOA provider to offer the electronic version of the M.I.N.I on tablets and the web for global clinical trials. PHT is adding more services and capabilities trial sponsors are requesting to make it easier to implement eCOA Systems in clinical trials. In addition to making the M.I.N.I available on the SitePad and NetPRO Systems, PHT is also offering rater training services to ensure the proper implementation of the instrument by clinicians."

Dr. Susan M. Dallabrida, Vice President of PHT Clinical Science & Consulting, explained, "This electronic version of the M.I.N.I. is the only authorized electronic, Sheehan-certified version of the M.I.N.I. 6.0 by a third party. PHT has invested considerable resources to bring the M.I.N.I. to the SitePad System and is delighted to serve as a preferred provider. Requests for PHT to manage the license agreements of validated questionnaires, handle translations and develop migrations from paper PRO to ePRO, in full compliance with FDA Guidance, are increasing."

Learn about the latest PRO and eCOA innovations, case studies and best practices at the 2014 PRO & eCOA Congress at bit.ly/CongressBarcelona. Learn more about the PRO & eCOA Congress in one minute: http://bit.ly/1h39AHS.

About PHT Corporation
PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for better clinical research. The PHT electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from the latest mobile devices. PHT scientific, regulatory and technological expertise combined with quality outcomes data enable clients to make research decisions with confidence. Sponsors and CROs have leveraged the PHT Patient Suite in 650+ trials resulting in 16+ regulatory approvals. Visit phtcorp.com for more information on PHT. Follow PHT on LinkedIn, Facebook, Twitter, Google+ and YouTube.

Contacts

For PHT Corporation
Brenda Nashawaty, 617-688-3253
[email protected]

 

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.